DelveInsight's "ENTYVIO Market Size, Forecast, and Market Insight Report" highlights the details around ENTYVIO, a gut-selective biologic developed by Takeda Pharmaceutical. The report provides ...

The presentation corroborated an earlier Phase I trial findings in healthy individuals, suggesting that the oral selective α4β7 integrin inhibitor could significantly block the binding of ...

The study further explored the molecular mechanisms of KLX's action, revealing that KLX activates FGFR1, which in turn activates MAP4K4, leading to the inactivation of integrin β1 and the ...

Xintela has amended the study protocol in the clinical phase I/IIa study with XSTEM on patients with difficult-to-heal venous leg ulcers to complete the study earlier. The number of patients to be enr ...